AXT Secures Up to US$545M Private Equity Financing for Tongmei, Injecting US$400M Itself
AXTI has more than doubled off its 52-week low of $5.86.
Summary
AXT's majority-owned Tongmei signed definitive agreements for a private equity investment of RMB 1.91-3.67 billion (about US$285-545 million), with AXT itself subscribing for 342,998,797 Tongmei shares worth US$400 million. At the maximum amount, AXT would keep roughly 73.40% of Tongmei, and closing is targeted for December 2026 pending Chinese regulatory filings.
Key Events · Financing and Capital Events · AXTI
-
Tongmei Raises Up to US$545M
Definitive agreements with BNK-B3 HK Holdings and other institutional investors cover a minimum of RMB 1,912,350,000 (~US$285 million) and a maximum of RMB 3,668,639,053.25 (~US$545 million) in Tongmei ordinary shares.
-
AXT Injects US$400M Into Tongmei
AXT agreed to subscribe for 342,998,797 Tongmei ordinary shares for the RMB equivalent of US$400 million on or before closing, funding capacity expansion from the parent's own balance sheet rather than issuing AXT stock.
-
AXT Stake Slips to ~73.40%
Assuming the Maximum Amount, AXT expects to own approximately 73.40% of Tongmei and continue consolidating it; the Lead Investor gets one of nine Tongmei board seats plus consent, preemptive and liquidation-preference rights.
-
Redemption Right With 8% Accrual
Investors can force Tongmei to redeem if no Qualified IPO (13% IRR threshold) occurs within three years, at the subscription price plus 8% per annum compounded and unpaid dividends; AXT may elect to buy the shares instead, in cash, an unsecured promissory note, or AXT common stock.
Analysis · AXTI · Manufacturing
Tongmei is raising RMB 1.91-3.67 billion (roughly US$285-545 million) directly at the subsidiary level, and AXT is contributing another US$400 million of its own by subscribing for 342,998,797 Tongmei shares. That is real money aimed at indium phosphide wafer capacity while demand outruns supply, and it is raised at Tongmei rather than by selling AXT stock, so AXT shareholders are not diluted at the parent. The trade-off is structural: AXT's stake falls to about 73.40% at the maximum amount, the new investors get a board seat, consent and preemptive rights, and a redemption right that pays 8% a year compounded if Tongmei has not completed a Qualified IPO within three years. AXT can be called on to buy those shares back in cash or stock, a contingent obligation layered on top of the previously disclosed Tongmei redemption exposure. Closing depends on PRC governmental filings and must happen by December 20, 2026 or the subscription agreement terminates.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXTI was trading at $59.28 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $5.86 to $143.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.